Study demonstrated 100% efficacy in prevention of parvovirus infection in prophylactic pivotal study of KIND-030 San Francisco, California (September 16, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030, a monoclonal antibody targeting canine […]
SAN FRANCISCO, September 9, 2020 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will participate in the H.C. Wainwright Global Investment Conference on September 14-15, the Cantor Global Healthcare Conference on September 16, and the Lake Street Best Ideas Growth Conference on September 17. Dr. Richard Chin, […]
/wp-content/uploads/2017/09/KindredBioHeader2017.png00Katja Buhrer/wp-content/uploads/2017/09/KindredBioHeader2017.pngKatja Buhrer2020-09-09 08:06:482020-09-09 08:06:49Kindred Biosciences to Participate in H.C. Wainwright Global Investment Conference, Cantor Global Healthcare Conference and Lake Street Best Ideas Growth Conference
San Francisco, California (August 5, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2020 and provided updates on its programs. For the second quarter of 2020, KindredBio reported net revenues of $39.6 million […]
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Wednesday, August 5, 2020. San Francisco, California (July 23, 2020) — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its second quarter 2020 financial results on August 5, […]
San Francisco, California (June 8, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced a plan to enhance its strategic position. The company will prioritize its most attractive late stage programs and substantially reduce expenses to best position it for success with the […]
/wp-content/uploads/2017/09/KindredBioHeader2017.png00Katja Buhrer/wp-content/uploads/2017/09/KindredBioHeader2017.pngKatja Buhrer2020-06-08 16:04:282020-06-08 16:04:30Kindred Biosciences Announces Plan to Strengthen its Strategic Position
-0.02 (-0.45%)
Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody
/in Frontpage, Investor, News /by Katja BuhrerStudy demonstrated 100% efficacy in prevention of parvovirus infection in prophylactic pivotal study of KIND-030 San Francisco, California (September 16, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030, a monoclonal antibody targeting canine […]
Kindred Biosciences to Participate in H.C. Wainwright Global Investment Conference, Cantor Global Healthcare Conference and Lake Street Best Ideas Growth Conference
/in Frontpage, Investor, News /by Katja BuhrerSAN FRANCISCO, September 9, 2020 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will participate in the H.C. Wainwright Global Investment Conference on September 14-15, the Cantor Global Healthcare Conference on September 16, and the Lake Street Best Ideas Growth Conference on September 17. Dr. Richard Chin, […]
Kindred Biosciences Announces Second Quarter 2020 Financial Results
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (August 5, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2020 and provided updates on its programs. For the second quarter of 2020, KindredBio reported net revenues of $39.6 million […]
Kindred Biosciences to Announce Second Quarter 2020 Financial Results
/in Frontpage, Investor, News /by Katja BuhrerCompany to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Wednesday, August 5, 2020. San Francisco, California (July 23, 2020) — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its second quarter 2020 financial results on August 5, […]
Kindred Biosciences Announces Plan to Strengthen its Strategic Position
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (June 8, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced a plan to enhance its strategic position. The company will prioritize its most attractive late stage programs and substantially reduce expenses to best position it for success with the […]